When alcohol giant Diageo decided to buy Hollywood actor George Clooney’s tequila brand, Casamigos, for up to $1 billion, Jim Cramer instantly took notice. “It’s not very often that I get to talk about one of my favorite subjects on air: tequila,” the “Mad Money” host said. At first glance, what intrigued Cramer most was […]
Read moreEuropean markets today are positioned much like U.S. markets were three years ago, creating a new sense of optimism overseas, an analyst said Wednesday. “They are seeing economic strength and earnings growth and with cheap valuations,” RiverFront Investment Group’s Doug Sandler said on CNBC’s “Closing Bell.” A recent shift in the European political landscape is […]
Read more
Canaccord Genuity’s Tony Dwyer is using just one chart to show the bears that stocks are moving higher. “There’s this narrative out there that the yield curve flattening is telling you that the economy is closer to recession and the stock market is in trouble. History shows the opposite is true,” the firm’s chief market […]
Read moreTalk about a solid track record. Four stocks in the S&P 500 — Nvidia, Broadcom, Reynolds American and Fiserv — have risen by more than 15 percent in each of the last four years. In 2017, the four are rising even faster: more than 20 percent. Nvidia has seen explosive gains, having risen over 1,000 […]
Read moreWith investors in an endless conflict of growth versus value, Jim Cramer wanted to right the record about the stock market’s current darlings, high-growth names. “As the creator of FANG, my fabulous acronym for Facebook, Amazon, Netflix and Google, now Alphabet, I think I have a good read on what’s hot and what’s not,” the […]
Read more
The price of ethereum, a bitcoin rival, fell more than 15.5 percent Wednesday amid a flood of demand and increased worries it may face a divisive debate on how to upgrade its network. Ethereum, also known as ether, traded near $303 Wednesday afternoon, according to CoinDesk. The sharp fall comes after ethereum shot up more […]
Read moreBiotech stocks are on a tear, on pace for their best weekly performance of 2017, as word from Washington indicates President Donald Trump’s expected action on drug prices may not be as onerous as investors feared. But hold on. Trump hasn’t yet publicly acted on drug prices — sources told CNBC this week the administration […]
Read moreBiotech stocks have been on a tear this week. The SPDR S&P Biotech (XBI) exchange-traded fund climbed more than 3 percent on Wednesday, putting it on track to post its best weekly performance since March 13. The biotech ETF has already outperformed the broader market year to date, rising 30 percent in the period. The […]
Read moreThe fields outside Mohall, North Dakota , were until recently a collage of blue flax, yellow sunflowers and amber wheat. But today many are uniform patches of green at the peak of the summer growing season. This new landscape is thanks to farmers such as Eric Moberg, whose 72-row air seeder planted thousands of acres […]
Read moreSaudi Arabia’s newly named Crown Prince Mohammed bin Salman is unlikely to make changes to oil production policy, but his more aggressive foreign policy stance could at some point put a political risk premium back in the price of oil, according to RBC’s Helima Croft. King Salman Wednesday named his 31-year-old son to be his […]
Read more